Canine Lymphoma: Welfare-Centred Chemotherapy and Quality of Life

Lymphoma is among the most common cancers in dogs and responds well to chemotherapy. Welfare-centred oncology balances treatment efficacy with quality of life throughout the journey.

Key Facts

Lymphoma accounts for approximately 7-14% of all canine cancers, making it one of the most frequently diagnosed
Golden Retrievers, Boxers, and Labrador Retrievers have elevated lymphoma incidence
Multi-agent CHOP-based chemotherapy achieves complete remission in 60-90% of dogs
Median survival with treatment is 12-16 months; median survival without treatment is 4-8 weeks

Welfare Considerations

Chemotherapy welfare considerations differ between dogs and humans — most dogs tolerate CHOP protocols well with minimal side effects when dosed appropriately. Welfare monitoring includes appetite, energy levels, gastrointestinal signs, and haematological parameters. Side effects when they occur include nausea, inappetence, and rarely severe neutropenia. Quality of life is usually maintained throughout most of the treatment period. Welfare-centred oncology establishes clear welfare thresholds for treatment modification or discontinuation.

What You Can Do

Seek veterinary oncology referral promptly for lymphoma diagnosis to access evidence-based treatment options
Establish clear welfare thresholds with your oncologist for when treatment modification is indicated
Monitor daily food intake, energy levels, and faecal quality as routine home welfare monitoring during chemotherapy
Use validated quality-of-life tools to communicate welfare status between home observations and clinical visits